MedTrace Logo

Safety of ENC-201-CED ENCRT

NCT06408311 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-11

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

COMBINATION_PRODUCT

ENC-201-CED hPI

macro-encapsulated human primary islets

Sponsors & Collaborators

  • resCON Research

    collaborator UNKNOWN

  • Encellin

    lead INDUSTRY

Principal Investigators

  • Grace Wei, PhD · Encellin

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2026-07-31
Completion
2026-10-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408311 on ClinicalTrials.gov